Giorgos Karakousis

Prof. Giorgos Karakousis


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2014 in Cancer
Verified
Journal Article
Open access
PDF file
EBEdmund K. Bartlett
Edmund K. Bartlett
KSKristina D. Simmons
Kristina D. Simmons
HWHeather Wachtel
Heather Wachtel
RRRobert E. Roses
Robert E. Roses
DFDouglas L. Fraker
Douglas L. Fraker
GKGiorgos Karakousis
Giorgos Karakousis
BACKGROUND: Although studies of metastasectomy have been limited primarily to institutional experiences, reports of favorable long‐term outcomes have generated increasing interest. In the current study, the authors attempted to define the national practice patterns in metastasectomy for 4 common malignancies with varying responsiveness to systemic therapy.METHODS: The National (Nationwide) Inpatient Sample was used to estimate the national incidence of metastasectomy for colorectal cancer, lung cancer, breast cancer, and melanoma from 2000 through 2011. Incidence‐adjusted rates were determined for liver, lung, brain, small bowel, and adrenal metastasectomies. The average annual percentage change (AAPC) in metastasectomy by cancer type was calculated using joinpoint regression.RESULTS: Colorectal cancer was the most common indication for metastasectomy (87,407 cases; 95% confidence interval [95% CI], 86,307‐88,507 cases) followed by lung cancer (58,245 cases; 95% CI, 57,453‐59,036 cases), breast cancer (26,271 cases; 95% CI, 25,672‐26,870 cases), and melanoma (20,298 cases; 95% CI, 19,897‐20,699 cases). Metastasectomy increased significantly for all cancer types over the study period: colorectal cancer (AAPC, 6.83; 95% CI, 5.7‐7.9), lung cancer (AAPC, 5.8; 95% CI, 5.1‐6.4), breast cancer (AAPC, 5.5; 95% CI, 3.7‐7.3), and melanoma (AAPC, 4.03; 95% CI, 2.1‐6.0). Despite an increasing number of comorbidities in patients undergoing metastasectomy (P<.05 for each cancer type), inpatient mortality rates after metastasectomy fell for all cancer types, most significantly for colorectal (AAPC, −5.49; 95% CI, −8.2 to −2.7) and lung (AAPC, −6.2; 95% CI, −11.7 to −0.3) cancers. The increasing performance of metastasectomy was largely driven by high‐volume institutions, in which patients had a lower mean number of comorbidities (P<.01 for all cancer types) and lower inpatient mortality (P<.01 for all cancers except melanoma).CONCLUSIONS: From 2000 through 2011, the performance of metastasectomy increased substantially across common cancer types, notwithstanding various advances in systemic therapies. Metastasectomy was performed more safely, despite increasing patient comorbidity. High‐volume institutions appeared to drive practice patterns. Cancer 2015;121:747–757. © 2014 American Cancer Society.

1 February 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JMJahan J Mohiuddin
Jahan J Mohiuddin
BCBrian Chu
Brian Chu
AFAndrea Facciabene
Andrea Facciabene
KPKendra Poirier
Kendra Poirier
XWXingmei Wang
Xingmei Wang
JLJohn N Lukens
John N Lukens
Gut microbial diversity is associated with improved response to immune checkpoint inhibitors (ICI). Based on the known detrimental impact that antibiotics have on microbiome diversity, we hypothesized that antibiotic receipt prior to ICI would be associated with decreased survival. Patients with stage III and IV melanoma treated with ICI between 2008 and 2019 were selected from an institutional database. A window of antibiotic receipt within 3 months prior to the first infusion of ICI was prespecified. The primary outcome was overall survival (OS), and secondary outcomes were melanoma-specific mortality and immune-mediated colitis requiring intravenous steroids. All statistical tests were two-sided. There were 568 patients in our database of which 114 received antibiotics prior to ICI. Of the patients, 35.9% had stage III disease. On multivariable Cox proportional hazards analysis of patients with stage IV disease, the antibiotic-exposed group had statistically significantly worse OS (hazard ratio [HR] = 1.81, 95% confidence interval [CI] = 1.27 to 2.57; P <.001). The same effect was observed among antibiotic-exposed patients with stage III disease (HR = 2.78, 95% CI = 1.31 to 5.87; P =.007). When limited to only patients who received adjuvant ICI (n = 89), antibiotic-exposed patients also had statistically significantly worse OS (HR = 4.84, 95% CI = 1.09 to 21.50; P =.04). The antibiotic group had a greater incidence of colitis (HR = 2.14, 95% CI = 1.02 to 4.52; P =.046). Patients with stage III and IV melanoma exposed to antibiotics prior to ICI had statistically significantly worse OS than unexposed patients. Antibiotic exposure was associated with greater incidence of moderate to severe immune-mediated colitis. Given the large number of antibiotics prescribed annually, physicians should be judicious with their use in cancer populations likely to receive ICI.

1 February 2016
Verified
Journal Article
Open access
PDF file
ANAndrew D. Newton
Andrew D. Newton
EBEdmund K. Bartlett
Edmund K. Bartlett
GKGiorgos Karakousis
Giorgos Karakousis
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality

1 September 2017 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
ASAndrew J. Sinnamon
Andrew J. Sinnamon
MNMadalyn G. Neuwirth
Madalyn G. Neuwirth
PYPratyusha Yalamanchi
Pratyusha Yalamanchi
PGPhyllis Gimotty
Phyllis Gimotty
DEDavid E. Elder
David E. Elder
GKGiorgos Karakousis
Giorgos Karakousis
Approximately 85% of new invasive melanoma diagnoses present with stage I and II disease.1 Among these, more than 70% are category T1 tumors (≤1.0 mm) and, despite the overall excellent prognosis for this subgroup of patients, those with T1 tumors represent the largest public mortality burden due to their overall high prevalence.2 However, the use of sentinel lymph node biopsy (SLNB) remains controversial in this population due to overall low yield of identifying occult nodal disease. Proper patient selection for SLNB is critical for reducing cost and perioperative morbidity while simultaneously recognizing patients in whom SLNB carries value. These points are magnified given the volume of patients with clinically localized T1 melanoma seen in consultation annually.


1 February 2016
Verified
Journal Article
Open access
PDF file
MNMadalyn G. Neuwirth
Madalyn G. Neuwirth
HAH. Richard Alexander
H. Richard Alexander
GKGiorgos Karakousis
Giorgos Karakousis
Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective